ID

31007

Descrizione

Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Keywords

versioni (1)
  1. 10/07/18 10/07/18 -
Titolare del copyright

see clinicaltrials.gov

Caricato su

10 luglio 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755

Inglese

Patient Enrollment

1 moduli  
  1. StudyEvent: ODM
    1. Patient Enrollment
Demographics
Descrizione

Demographics

Alias
UMLS CUI-1
C1704791
Patient Body Weight
Descrizione

Body Weight

Tipo di dati

float

Unità di misura
  • kg
Alias
UMLS CUI [1]
C0005910
kg
Patient Height
Descrizione

Patient Height

Tipo di dati

float

Unità di misura
  • cm
Alias
UMLS CUI [1]
C0005890
cm
Date of Birth
Descrizione

Date of Birth

Tipo di dati

date

Alias
UMLS CUI [1]
C0421451
Gender
Descrizione

Gender

Tipo di dati

text

Alias
UMLS CUI [1]
C0079399
Lymphoid Neoplasms
Descrizione

Lymphoid Neoplasms

Alias
UMLS CUI-1
C1518071
UMLS CUI-2
C0027627
Does the patient have a histologically confirmed diagnosis of B-cell CLL/PLL/SLL; lymphoplasmacytic-immunocytoma; follicle center, follicular, grade I; or follicle center, follicular grade II non-Hodgkin's lymphoma or one of these B-cell lymphomas which has transformed to a more aggressive histology [according to Revised European-American classification of Lymphoid Neoplasms (REAL)]?
Descrizione

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Leukemia, Prolymphocytic, B-Cell; Malignant lymphoma - lymphoplasmacytic; Lymphoma, Non-Hodgkin, Grade one rank; Lymphoma, Non-Hodgkin, Grade two rank; Aggressive Non-Hodgkin Lymphoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1302547
UMLS CUI [2]
C0475801
UMLS CUI [3]
C0334633
UMLS CUI [4,1]
C0024305
UMLS CUI [4,2]
C0687695
UMLS CUI [5,1]
C0024305
UMLS CUI [5,2]
C0441802
UMLS CUI [6]
C1332225
Date of original diagnosis
Descrizione

Lymphoid Neoplasm Metastasis, Date of diagnosis

Tipo di dati

date

Alias
UMLS CUI [1,1]
C1518071
UMLS CUI [1,2]
C0027627
UMLS CUI [1,3]
C2316983
REAL lymphoma histology at initial diagnosis
Descrizione

Lymphoid Neoplasm Metastasis, Classification International, at initial diagnosis

Tipo di dati

text

Alias
UMLS CUI [1,1]
C1518071
UMLS CUI [1,2]
C0027627
UMLS CUI [1,3]
C0008902
UMLS CUI [1,4]
C1512888
UMLS CUI [1,5]
C4071762
Has transformation occurred?
Descrizione

Lymphoid Neoplasm Metastasis, cell transformation

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1518071
UMLS CUI [1,2]
C0027627
UMLS CUI [1,3]
C0040682
Date of transformation
Descrizione

Lymphoid Neoplasm Metastasis, cell transformation, Date in time

Tipo di dati

date

Alias
UMLS CUI [1,1]
C1518071
UMLS CUI [1,2]
C0027627
UMLS CUI [1,3]
C0040682
UMLS CUI [1,4]
C0011008
Sites of disease at enrollment
Descrizione

Lymphoid Neoplasm Metastasis, Anatomic Site, Enrollment

Tipo di dati

text

Alias
UMLS CUI [1,1]
C1518071
UMLS CUI [1,2]
C0027627
UMLS CUI [1,3]
C1515974
UMLS CUI [1,4]
C1516879
CD20 antigen
Descrizione

CD20 antigen

Alias
UMLS CUI-1
C0054946
Does the patient have evidence that their tumor tissue expresses the CD20 antigen? Immunoperoxidase stains of paraffin embedded tissue showing positive reactivity with L26 antibody or immunoperoxidase stains of frozen tissue showing positive reativity with Anti-B1 Antibody (>50% of tumor cells are positive) or evidence of CD20 positivity by flow cytometry (>50% of tumor cells are positive) are acceptable evidence of CD20 positivity. Testing of tumor tissue from any time in the course of the patient's disease is acceptable.
Descrizione

Antigens, Gene Expression, Tumor tissue sample, Evidence

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0054946
UMLS CUI [1,2]
C0017262
UMLS CUI [1,3]
C0475358
UMLS CUI [1,4]
C3887511
Prior chemotherapy
Descrizione

Prior chemotherapy

Alias
UMLS CUI-1
C1514457
Has the patient received 1 or 2 prior chemotherapy regimens and progressed following the last regimen? Patients who have received >2 prior chemotherapy regimens are excluded. Prior therapy with radiation, immunosuppressants, or steroids are not counted as chemotherapy regimens
Descrizione

Prior Chemotherapy; Disease Progression

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0242656
Karnofsky Performance Status; Survival time, Anticipated
Descrizione

Karnofsky Performance Status; Survival time, Anticipated

Alias
UMLS CUI-1
C0206065
UMLS CUI-2
C2919552
UMLS CUI-3
C3840775
Does the patient have a performance status of at least 60% on the Karnofsky Scale and an anticipated survival of at least 3 months?
Descrizione

Karnofsky Performance Status; Survival time, Anticipated

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0206065
UMLS CUI [2,1]
C2919552
UMLS CUI [2,2]
C3840775
ANC; Platelet Count
Descrizione

ANC; Platelet Count

Alias
UMLS CUI-1
C0948762
UMLS CUI-2
C0032181
Does the patient have an absolute granulocyte count (ANC) >1,500 cells x 10⁹/l and a platelet count >100,000 cells x 10⁹/l within 14 days of study entry? These blood counts must be sustained without support of hematopoietic cytokines or transfusion of blood products.
Descrizione

ANC; Platelet Count

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0948762
UMLS CUI [2]
C0032181
Date
Descrizione

Absolute neutrophil count, Date in time; Platelet Count measurement, Date in time

Tipo di dati

date

Alias
UMLS CUI [1,1]
C0948762
UMLS CUI [1,2]
C0011008
UMLS CUI [2,1]
C0032181
UMLS CUI [2,2]
C0011008
ANC
Descrizione

ANC

Tipo di dati

float

Alias
UMLS CUI [1]
C0948762
Platelet count
Descrizione

Platelet count

Tipo di dati

float

Alias
UMLS CUI [1]
C0032181
Renal function; Hepatic function
Descrizione

Renal function; Hepatic function

Alias
UMLS CUI-1
C0232804
UMLS CUI-2
C0232741
Does the patient have adequate renal function (defined as serum creatinine < 1,5 x upper limit of normal) and hepatic function [defined as total bilirubin < 1,5 x upper limit of normal and hepatic transaminases (AST + ALT) < 5 x upper limit of normal] within 14 days of study entry?
Descrizione

Renal function; Hepatic function

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0232804
UMLS CUI [2]
C0232741
undefined item
Descrizione

undefined item

Tipo di dati

text

Bi-dimensionally measured disease
Descrizione

Bi-dimensionally measured disease

Alias
UMLS CUI-1
C1513041
UMLS CUI-2
C1705052
Does the patient have bi-dimensionally measured disease? At least one lesion must be ≥ 2 x 2 cm (by CT scan).
Descrizione

Bi-dimensionally measured disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1705052
Age
Descrizione

Age

Alias
UMLS CUI-1
C0001779
Is the patient at least 18 years of age?
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
Informed Consent
Descrizione

Informed Consent

Alias
UMLS CUI-1
C0021430
Has the patient signed the Ethics Committee-approved written informed consent form prior to study entry?
Descrizione

Informed consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
Date consent signed
Descrizione

Informed Consent Date

Tipo di dati

date

Alias
UMLS CUI [1]
C2985782
Exclusion criteria
Descrizione

Exclusion criteria

Alias
UMLS CUI-1
C0680251
Does the patient have an average of >25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens as assessed microscopically within 42 days of study entry? Bilateral posterior ilia crest biopsies are required if the percentage of intratrabecular space involved exceeds 10% on a unilateral biopsy. The mean of bilateral biopsies must be no more than 25%.
Descrizione

Lymphoma, Bone Marrow

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0024299
UMLS CUI [1,2]
C0005953
Has the patient received cytotoxic chemotherapy, radiation therapy, or cytokine treatment within 4 weeks prior to study entry (six weeks for nitrosourea compounds) or exhibited persistent clinical evidence of toxicity? The use of systemic steroids must be discontinued 1 week prior to study entry.
Descrizione

Prior Chemotherapy, Cytotoxic; Therapeutic radiology procedure, Before; Cytokine therapy, Before; Toxicity aspects

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0677881
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C0332152
UMLS CUI [3,1]
C0199974
UMLS CUI [3,2]
C0332152
UMLS CUI [4]
C0040539
Has the patient undergone prior hematopoietic stem cell transplant following high dose chemotherapy or chemo/radiotherapy?
Descrizione

Hemopoietic stem cell transplant Following Chemotherapy Regimen; Hemopoietic stem cell transplant Following Therapeutic radiology procedure

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0472699
UMLS CUI [1,2]
C0332282
UMLS CUI [1,3]
C0392920
UMLS CUI [2,1]
C0472699
UMLS CUI [2,2]
C0332282
UMLS CUI [2,3]
C1522449
Does the patient have active obstructive hydronephrosis?
Descrizione

Hydronephrosis, Obstructed, Active

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020295
UMLS CUI [1,2]
C0549186
UMLS CUI [1,3]
C0205177
Does the patient have evidence of active infection requiring intravenous antibiotics at the time of study entry?
Descrizione

Communicable Diseases; Antibiotics, Intravenous

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0003232
UMLS CUI [1,3]
C0348016
Does the patient have New York Heart Association class III or IV heart disease or other serious illness that would preclude evaluation?
Descrizione

New York Heart Association Classification; Illness, Serious

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1275491
UMLS CUI [2,1]
C0221423
UMLS CUI [2,2]
C0205404
Has the patient had prior malignancy other than lymphoma, except for adequately treated skin cancer, in-situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years?
Descrizione

Malignant Neoplasms, Before

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0332152
Does the patient have known HIV infection?
Descrizione

HIV infection

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019693
Does the patient have known brain or leptomeningeal metastases?
Descrizione

Metastatic malignant neoplasm to brain; Metastatic Malignant Neoplasm to the Leptomeninges

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2]
C1704231
Is the patient pregnant or breast-feeding? Patients of childbearing potential must have a negative pregnancy test result within 7 days of study entry and radiolabeled antibody is not to be administered until a negative result is obtained.
Descrizione

Pregnancy; Breast Feeding

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Has the patient had previous allergic reaction to iodine (with the exception of reactions to intravenous iodine-containing contrast materials)?
Descrizione

Iodine, Allergic reaction

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0021968
UMLS CUI [1,2]
C1527304
Has the patient previously been given any monoclonal or polyclonal antibodies of any non-human species for either diagnostic or therapeutic purposes? This includes engineered chimeric and humanized antibodies.
Descrizione

Monoclonal Antibodies; Polyclonal antibody

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0003250
UMLS CUI [2]
C0312586
Has the patient previously received radioimmunotherapy?
Descrizione

Radioimmunotherapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0085101
Has the patient had progressive disease within one year of irradiation arising in a field that has been previously irradiated with > 3500 cGy?
Descrizione

Progressive Neoplastic Disease, Response to treatment, Radiation Dosage

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0677932
UMLS CUI [1,2]
C0521982
UMLS CUI [1,3]
C0034524
Is the patient concurrently receiving either approved or non-approved (through another protocol) anti-cancer drugs or biologics?
Descrizione

cancer treatment, Concurrent

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205420
Has the patient received >2 prior chemotherapy regimens? Prior therapy with radiation, immunosuppressants, or steroids are not counted as chemotherapy regimens.
Descrizione

Prior Chemotherapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1514457
Ritorna all'inizio della pagina

Similar models

Patient Enrollment

1 moduli
  1. StudyEvent: ODM
    1. Patient Enrollment
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Demographics
C1704791 (UMLS CUI-1)
Body Weight
Item
Patient Body Weight
float
C0005910 (UMLS CUI [1])
Patient Height
Item
Patient Height
float
C0005890 (UMLS CUI [1])
Date of Birth
Item
Date of Birth
date
C0421451 (UMLS CUI [1])
Item
Gender
text
C0079399 (UMLS CUI [1])
Gender
Code List
Gender
CL Item
Male (1)
CL Item
Female (2)
Item Group
Lymphoid Neoplasms
C1518071 (UMLS CUI-1)
C0027627 (UMLS CUI-2)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Leukemia, Prolymphocytic, B-Cell; Malignant lymphoma - lymphoplasmacytic; Lymphoma, Non-Hodgkin, Grade one rank; Lymphoma, Non-Hodgkin, Grade two rank; Aggressive Non-Hodgkin Lymphoma
Item
Does the patient have a histologically confirmed diagnosis of B-cell CLL/PLL/SLL; lymphoplasmacytic-immunocytoma; follicle center, follicular, grade I; or follicle center, follicular grade II non-Hodgkin's lymphoma or one of these B-cell lymphomas which has transformed to a more aggressive histology [according to Revised European-American classification of Lymphoid Neoplasms (REAL)]?
boolean
C1302547 (UMLS CUI [1])
C0475801 (UMLS CUI [2])
C0334633 (UMLS CUI [3])
C0024305 (UMLS CUI [4,1])
C0687695 (UMLS CUI [4,2])
C0024305 (UMLS CUI [5,1])
C0441802 (UMLS CUI [5,2])
C1332225 (UMLS CUI [6])
Lymphoid Neoplasm Metastasis, Date of diagnosis
Item
Date of original diagnosis
date
C1518071 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C2316983 (UMLS CUI [1,3])
Item
REAL lymphoma histology at initial diagnosis
text
C1518071 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0008902 (UMLS CUI [1,3])
C1512888 (UMLS CUI [1,4])
C4071762 (UMLS CUI [1,5])
undefined item
Code List
REAL lymphoma histology at initial diagnosis
CL Item
B-cell CLL/PLL/SLL (B-cell CLL/PLL/SLL)
CL Item
lymphoplasmacytic-immunocytoma (lymphoplasmacytic-immunocytoma)
CL Item
follicle center, follicular, grade I (follicle center, follicular, grade I)
CL Item
follicle center, follicular, grade II (follicle center, follicular, grade II)
Lymphoid Neoplasm Metastasis, cell transformation
Item
Has transformation occurred?
boolean
C1518071 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0040682 (UMLS CUI [1,3])
Lymphoid Neoplasm Metastasis, cell transformation, Date in time
Item
Date of transformation
date
C1518071 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0040682 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
Item
Sites of disease at enrollment
text
C1518071 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C1515974 (UMLS CUI [1,3])
C1516879 (UMLS CUI [1,4])
at enrollment
Code List
Sites of disease at enrollment
CL Item
Head (Head)
CL Item
Abdomen (Abdomen)
CL Item
Neck (Neck)
CL Item
Pelvis (Pelvis)
CL Item
Chest (Chest)
CL Item
Skin (Skin)
CL Item
Other (Other)
Item Group
CD20 antigen
C0054946 (UMLS CUI-1)
Antigens, Gene Expression, Tumor tissue sample, Evidence
Item
Does the patient have evidence that their tumor tissue expresses the CD20 antigen? Immunoperoxidase stains of paraffin embedded tissue showing positive reactivity with L26 antibody or immunoperoxidase stains of frozen tissue showing positive reativity with Anti-B1 Antibody (>50% of tumor cells are positive) or evidence of CD20 positivity by flow cytometry (>50% of tumor cells are positive) are acceptable evidence of CD20 positivity. Testing of tumor tissue from any time in the course of the patient's disease is acceptable.
boolean
C0054946 (UMLS CUI [1,1])
C0017262 (UMLS CUI [1,2])
C0475358 (UMLS CUI [1,3])
C3887511 (UMLS CUI [1,4])
Item Group
Prior chemotherapy
C1514457 (UMLS CUI-1)
Prior Chemotherapy; Disease Progression
Item
Has the patient received 1 or 2 prior chemotherapy regimens and progressed following the last regimen? Patients who have received >2 prior chemotherapy regimens are excluded. Prior therapy with radiation, immunosuppressants, or steroids are not counted as chemotherapy regimens
boolean
C1514457 (UMLS CUI [1,1])
C0242656 (UMLS CUI [1,2])
Item Group
Karnofsky Performance Status; Survival time, Anticipated
C0206065 (UMLS CUI-1)
C2919552 (UMLS CUI-2)
C3840775 (UMLS CUI-3)
Karnofsky Performance Status; Survival time, Anticipated
Item
Does the patient have a performance status of at least 60% on the Karnofsky Scale and an anticipated survival of at least 3 months?
boolean
C0206065 (UMLS CUI [1])
C2919552 (UMLS CUI [2,1])
C3840775 (UMLS CUI [2,2])
Item Group
ANC; Platelet Count
C0948762 (UMLS CUI-1)
C0032181 (UMLS CUI-2)
ANC; Platelet Count
Item
Does the patient have an absolute granulocyte count (ANC) >1,500 cells x 10⁹/l and a platelet count >100,000 cells x 10⁹/l within 14 days of study entry? These blood counts must be sustained without support of hematopoietic cytokines or transfusion of blood products.
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
Absolute neutrophil count, Date in time; Platelet Count measurement, Date in time
Item
Date
date
C0948762 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
C0032181 (UMLS CUI [2,1])
C0011008 (UMLS CUI [2,2])
ANC
Item
ANC
float
C0948762 (UMLS CUI [1])
Platelet count
Item
Platelet count
float
C0032181 (UMLS CUI [1])
Item Group
Renal function; Hepatic function
C0232804 (UMLS CUI-1)
C0232741 (UMLS CUI-2)
Renal function; Hepatic function
Item
Does the patient have adequate renal function (defined as serum creatinine < 1,5 x upper limit of normal) and hepatic function [defined as total bilirubin < 1,5 x upper limit of normal and hepatic transaminases (AST + ALT) < 5 x upper limit of normal] within 14 days of study entry?
boolean
C0232804 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
undefined item
Item
text
Item Group
Bi-dimensionally measured disease
C1513041 (UMLS CUI-1)
C1705052 (UMLS CUI-2)
Bi-dimensionally measured disease
Item
Does the patient have bi-dimensionally measured disease? At least one lesion must be ≥ 2 x 2 cm (by CT scan).
boolean
C1513041 (UMLS CUI [1,1])
C1705052 (UMLS CUI [1,2])
Item Group
Age
C0001779 (UMLS CUI-1)
Age
Item
Is the patient at least 18 years of age?
boolean
C0001779 (UMLS CUI [1])
Item Group
Informed Consent
C0021430 (UMLS CUI-1)
Informed consent
Item
Has the patient signed the Ethics Committee-approved written informed consent form prior to study entry?
boolean
C0021430 (UMLS CUI [1])
Informed Consent Date
Item
Date consent signed
date
C2985782 (UMLS CUI [1])
Item Group
Exclusion criteria
C0680251 (UMLS CUI-1)
Lymphoma, Bone Marrow
Item
Does the patient have an average of >25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens as assessed microscopically within 42 days of study entry? Bilateral posterior ilia crest biopsies are required if the percentage of intratrabecular space involved exceeds 10% on a unilateral biopsy. The mean of bilateral biopsies must be no more than 25%.
boolean
C0024299 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
Prior Chemotherapy, Cytotoxic; Therapeutic radiology procedure, Before; Cytokine therapy, Before; Toxicity aspects
Item
Has the patient received cytotoxic chemotherapy, radiation therapy, or cytokine treatment within 4 weeks prior to study entry (six weeks for nitrosourea compounds) or exhibited persistent clinical evidence of toxicity? The use of systemic steroids must be discontinued 1 week prior to study entry.
boolean
C1514457 (UMLS CUI [1,1])
C0677881 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0199974 (UMLS CUI [3,1])
C0332152 (UMLS CUI [3,2])
C0040539 (UMLS CUI [4])
Hemopoietic stem cell transplant Following Chemotherapy Regimen; Hemopoietic stem cell transplant Following Therapeutic radiology procedure
Item
Has the patient undergone prior hematopoietic stem cell transplant following high dose chemotherapy or chemo/radiotherapy?
boolean
C0472699 (UMLS CUI [1,1])
C0332282 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
C0472699 (UMLS CUI [2,1])
C0332282 (UMLS CUI [2,2])
C1522449 (UMLS CUI [2,3])
Hydronephrosis, Obstructed, Active
Item
Does the patient have active obstructive hydronephrosis?
boolean
C0020295 (UMLS CUI [1,1])
C0549186 (UMLS CUI [1,2])
C0205177 (UMLS CUI [1,3])
Communicable Diseases; Antibiotics, Intravenous
Item
Does the patient have evidence of active infection requiring intravenous antibiotics at the time of study entry?
boolean
C0009450 (UMLS CUI [1,1])
C0003232 (UMLS CUI [1,2])
C0348016 (UMLS CUI [1,3])
New York Heart Association Classification; Illness, Serious
Item
Does the patient have New York Heart Association class III or IV heart disease or other serious illness that would preclude evaluation?
boolean
C1275491 (UMLS CUI [1])
C0221423 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
Malignant Neoplasms, Before
Item
Has the patient had prior malignancy other than lymphoma, except for adequately treated skin cancer, in-situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years?
boolean
C0006826 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
HIV infection
Item
Does the patient have known HIV infection?
boolean
C0019693 (UMLS CUI [1])
Metastatic malignant neoplasm to brain; Metastatic Malignant Neoplasm to the Leptomeninges
Item
Does the patient have known brain or leptomeningeal metastases?
boolean
C0220650 (UMLS CUI [1])
C1704231 (UMLS CUI [2])
Pregnancy; Breast Feeding
Item
Is the patient pregnant or breast-feeding? Patients of childbearing potential must have a negative pregnancy test result within 7 days of study entry and radiolabeled antibody is not to be administered until a negative result is obtained.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Iodine, Allergic reaction
Item
Has the patient had previous allergic reaction to iodine (with the exception of reactions to intravenous iodine-containing contrast materials)?
boolean
C0021968 (UMLS CUI [1,1])
C1527304 (UMLS CUI [1,2])
Monoclonal Antibodies; Polyclonal antibody
Item
Has the patient previously been given any monoclonal or polyclonal antibodies of any non-human species for either diagnostic or therapeutic purposes? This includes engineered chimeric and humanized antibodies.
boolean
C0003250 (UMLS CUI [1])
C0312586 (UMLS CUI [2])
Radioimmunotherapy
Item
Has the patient previously received radioimmunotherapy?
boolean
C0085101 (UMLS CUI [1])
Progressive Neoplastic Disease, Response to treatment, Radiation Dosage
Item
Has the patient had progressive disease within one year of irradiation arising in a field that has been previously irradiated with > 3500 cGy?
boolean
C0677932 (UMLS CUI [1,1])
C0521982 (UMLS CUI [1,2])
C0034524 (UMLS CUI [1,3])
cancer treatment, Concurrent
Item
Is the patient concurrently receiving either approved or non-approved (through another protocol) anti-cancer drugs or biologics?
boolean
C0920425 (UMLS CUI [1,1])
C0205420 (UMLS CUI [1,2])
Prior Chemotherapy
Item
Has the patient received >2 prior chemotherapy regimens? Prior therapy with radiation, immunosuppressants, or steroids are not counted as chemotherapy regimens.
boolean
C1514457 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial